anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Disclaimer

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 41,127
Current window 35,071-35,100
Pages 1,371
Rows per page 30
Component: Disclaimerclear collectionreset all
18 30 60

Component

35,071-35,100 of 41,127

filter-aware
50
The slide outlines a four-step laboratory workflow involving staining, lysis/fixation, loading, and algorithmic analysis.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
51
This slide is from the Theranos deck, illustrating their proprietary image processing pipeline.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
52
References CLSI EP05-A3 standard for precision performance testing.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
53
Includes FDA disclaimer and definitions for (L) and (N) cell counts.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
54
The slide uses a standard table format to define the parameters of a clinical validation study.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
55
The slide presents method comparison data (regression analysis) for three different cell types, including statistical metrics like r-squared, median bias, and Allowable Total Error (ATE).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
56
The slide shows three scatter plots with regression lines, R-squared values, and performance metrics (bias, ATE, TE).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
58
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
59
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
60
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
61
The slide compares the assay's LoD (480 copies/mL) against the CDC Zika test LoD (930 copies/mL).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
62
n = 3 replicates per test; FDA disclaimer present.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
63
The slide includes a disclaimer that the technology is not FDA cleared.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
64
n = 3 replicates per test; FDA disclaimer present.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
65
The slide includes a disclaimer at the bottom regarding FDA clearance status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
66
The slide presents experimental validation data for a diagnostic assay.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
67
Includes a standard Theranos FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
68
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
69
The slide includes a disclaimer that the technology is not FDA cleared.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
70
The slide highlights the third section with a teal background, indicating it is the current or focus topic.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
71
This slide outlines technical parameters for blood collection, likely part of a methodology or process overview.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
72
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
73
This slide outlines technical mitigation strategies for blood sample collection issues.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
74
The slide describes the mechanical process of the Theranos nanotainer system.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
75
The slide illustrates the mechanical process of blood collection and sample preparation.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
76
The image shows a Theranos-branded blood collection device (nanotainer).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
78
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Results1 hit
79
The slide uses a standard table format to define the parameters of a clinical validation study.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
80
The slide includes a disclaimer that the technology is not FDA cleared.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit
81
Passing-Bablok regression used for analysis.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Conclusion1 hit